Staphylococcus aureus alpha-hemolysin (Hla) and bicomponent leukocidins (Hla and leukocidins)

Staphylococcus aureus alpha-hemolysin (Hla) and bicomponent leukocidins are a group of potent pore-forming toxins that serve as critical virulence factors during infection. Alpha-hemolysin, or alpha-toxin, is a 33 kDa protein that assembles into a heptameric pore upon binding to its host receptor, ADAM10, leading to the lysis of epithelial cells, endothelial cells, and certain immune cells (Wilke & Bubeck Wardenburg, 2010). Bicomponent leukocidins, including Panton-Valentine Leukocidin (PVL), LukED, and LukAB, consist of S and F subunits that cooperatively form octameric pores on leukocytes by targeting specific G protein-coupled receptors and integrins (Spaan et al., 2017). These toxins collectively facilitate immune evasion by killing neutrophils and macrophages, while also promoting tissue damage and systemic inflammation (Alonzo & Torres, 2014). Because these toxins are secreted into the extracellular environment, they are accessible targets for monoclonal antibodies like Suvratoxumab and Tosatoxumab, which aim to neutralize the toxins and prevent cellular injury (Francois et al., 2021). Therapeutic development in this area focuses on reducing the severity of S. aureus-induced pneumonia and skin infections by mitigating toxin-mediated pathology. Clinical trials have explored these agents as adjunctive therapies to standard antibiotics to improve outcomes in high-risk patients.

Other names

Alpha-toxinHlaPanton-Valentine LeukocidinPVLGamma-hemolysinLukEDLukABLukGHPore-forming toxins

Neutralization of secreted toxins to prevent binding to host cell receptors and subsequent pore formation